ArticleStatistical methods in medical research2025
Augmented two-stage estimation for treatment switching in oncology trials: Leveraging external data for improved precision.
Article in Statistical methods in medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomized controlled trials in oncology often allow control group participants to switch to experimental treatments, a practice that, while often ethically necessary, complicates the accurate estimation of long-term treatment effects. When switching rates are high or sample sizes are limited, commonly used methods for treatment switching adjustment (such as the rank-preserving structural failure time model, inverse probability of censoring weights, and two-stage estimation) may produce imprecise estimates. Real-world data can be used to develop an external control arm for the randomized controlled trial, although this approach ignores evidence from trial subjects who did not switch and ignores evidence from the data obtained prior to switching for those subjects who did. This article introduces "augmented two-stage estimation" (ATSE), a method that combines data from non-switching participants in a randomized controlled trial with an external dataset, forming a "hybrid non-switching arm". While aiming for more precise estimation, the augmented two-stage estimation requires strong assumptions. Namely, conditional on all the observed covariates: (1) a participant's decision to switch treatments must be independent of their post-progression survival, and (2) individuals from the randomized controlled trial and the external cohort must be exchangeable. With a simulation study, we evaluate the augmented two-stage estimation method's performance compared to two-stage estimation adjustment and an external control arm approach. Results indicate that performance is dependent on scenario characteristics, but when unconfounded external data are available, augmented two-stage estimation may result in less bias and improved precision compared to two-stage estimation and external control arm approaches. When external data are affected by unmeasured confounding, augmented two-stage estimation becomes prone to bias, but to a lesser extent compared to an external control arm approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.